| Abstrakt: |
A recent study conducted by researchers at the Oswaldo Cruz Institute (FIOCRUZ) in Rio de Janeiro, Brazil, has explored the potential of new compounds in tissue engineering for the treatment of Chagas disease. The disease, which primarily affects socioeconomically vulnerable populations, currently lacks effective and safe drug therapies. The study focused on the evaluation of pyrazole-thiadiazole compounds and their anti-trypanosoma cruzi activity. The results showed promising antiparasitic activity and support the development of these compounds for potential clinical use. [Extracted from the article] |
